ClinicalTrials.gg

Program

GENSCI048

A development code. Also written as “GenSci048”.

Its studies are mostly in Uveitis · Endometriosis · Arthritis, Rheumatoid, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Nov 13, 20233 company-led studies, 3 open or runningNext primary completion: Dec 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical33 open or runningphase 2since Nov 13, 2023Nov 13, 2023Dec 14, 2027phase 2 · NCT07547995

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2023First study: phase 2 study in Systemic Sclerosis Associated Interstitial Lung DiseaseFirst studyNCT06189495 · 30 planned · China
  2. Apr 28, 2025Phase 2 study in Endometriosis-related PainNCT06963177 · 200 planned · China
  3. Apr 14, 2026Phase 2 study in UveitisNCT07547995 · 74 planned · China

Ahead

  1. Dec 14, 2027Primary completion: phase 2 study in UveitisNCT07547995
  2. May 15, 2028Primary completion: phase 2 study in Endometriosis-related PainNCT06963177

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07547995Uveitis · China2RecruitingDec 14, 202774
NCT06963177Endometriosis-related Pain · China2RecruitingMay 15, 2028200
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease · China2RecruitingMar 31, 202630

How it is read

Names in the registry

  • “GenSci048”, 3 entries

Codes read as this program: GENSCI048.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.